The online version of this article (doi:10.1007/s40122-014-0027-1) contains supplementary material, which is available to authorized users.
Neuropathic pain is a frequent and disabling condition with diverse underlying etiologies and is often difficult to treat. Systemic drug treatment is often limited in efficacy. Furthermore, adverse effects may be a limiting factor when trying to reach the necessary dose. Analgesics that can be applied topically have the potential to largely overcome this problem. They may be of particular advantage in localized neuropathic pain syndromes such as postherpetic neuralgia or small fiber neuropathy. Capsaicin, the pungent component of chili peppers, is a natural ligand of the transient receptor potential vanilloid 1 channel and has long been used as topically applicable cream with concentrations of 0.025 to 0.075%. In 2009, a high-concentration transdermal capsaicin 8% patch (Qutenza®; Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) was introduced for the treatment of peripheral neuropathic pain syndromes other than of diabetic origin in adults. It has since been widely used in diverse neuropathic pain disorders. In this review article, we summarize current knowledge on Qutenza, its advantages and problems, and expose unmet needs.
Tominaga M. Nociception and TRP channels. Handb Exp Pharmacol. 2007:489–505.
Baron R. Pharmakologische nicht-interventionelle Therapie chronisch neuropathischer Schmerzen. In: Diener HC, Weimar C, editors. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2012. p. 771–83.
Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manag. 2003;25:S12–7. CrossRef
Simone DA, Nolano M, Johnson T, Wendelschafer-Crabb G, Kennedy WR. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci. 1998;18:8947–59. PubMed
Kim JH, Ko JA, Kim JT, et al. Preparation of a capsaicin-loaded nanoemulsion for improving skin penetration. J Agric Food Chem. 2014 [Epub ahead of Print].
Acorda Therapeutics, Inc. Qutenza: Treatment Guide. Available from: http://www.qutenza.com/_docs/Qutenza%20Treatment%20Guide.pdf. Accessed April 14, 2014.
Committee for Medicinal Products for Human Use (CHMP). European Public Assessment Report—Qutenza. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000909/WC500040453.pdf. Accessed July 15, 2014.
Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. The Cochrane Database of Systematic Reviews. 2013;2:CD007393.
Clinicaltrials.gov. Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch (LIFT). Available from: http://clinicaltrials.gov/ct2/show/record/NCT01416116. Accessed April 14, 2014.
Maihöfner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1,044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29:673–83. PubMedCrossRef
Martini CH, Yassen A, Krebs-Brown A, et al. A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. Eur J Pain. 2013;17:1491–501. PubMed
- High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II